Back to Search
Start Over
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib
- Source :
- Future oncology (London, England). 15(21)
- Publication Year :
- 2019
-
Abstract
- Over the past 10 years, sorafenib has been the only systemic agent approved for the treatment of patients with unresectable hepatocellular carcinoma. Recently, lenvatinib was demonstrated noninferior to sorafenib, and regorafenib and ramucirumab were demonstrated superior to placebo in patients progressing on sorafenib and in patients with elevated α-fetoprotein-failing sorafenib, respectively. Phase I–II trials of immune checkpoint inhibitors reported promising efficacy signals. Recently, the randomized, placebo-controlled, Phase III CELESTIAL trial demonstrated statistically and clinically significant increase in overall survival from 8 months with placebo to 10.2 months with cabozantinib in patients failing sorafenib. Furthermore, the study showed a significant improvement in all the efficacy end points. Main adverse events were palmar–plantar erythrodysesthesia, hypertension, increased aspartate aminotransferase, fatigue and diarrhea.
- Subjects :
- 0301 basic medicine
Sorafenib
Oncology
Cancer Research
medicine.medical_specialty
Carcinoma, Hepatocellular
Cabozantinib
Pyridines
Drug Evaluation, Preclinical
Antineoplastic Agents
Placebo
Ramucirumab
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Regorafenib
medicine
Animals
Humans
Anilides
Molecular Targeted Therapy
Adverse effect
Protein Kinase Inhibitors
Neoplasm Staging
Randomized Controlled Trials as Topic
Clinical Trials as Topic
Molecular Structure
Neovascularization, Pathologic
business.industry
Liver Neoplasms
General Medicine
medicine.disease
Prognosis
digestive system diseases
030104 developmental biology
Treatment Outcome
chemistry
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Retreatment
business
Lenvatinib
medicine.drug
Subjects
Details
- ISSN :
- 17448301
- Volume :
- 15
- Issue :
- 21
- Database :
- OpenAIRE
- Journal :
- Future oncology (London, England)
- Accession number :
- edsair.doi.dedup.....faccf5f73d1cae2cb53a94496a4c462c